N
35.46
1.18 (3.44%)
| Previous Close | 34.28 |
| Open | 33.41 |
| Volume | 673,684 |
| Avg. Volume (3M) | 804,450 |
| Market Cap | 4,077,028,352 |
| Price / Sales | 180.30 |
| Price / Book | 5.76 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Operating Margin (TTM) | -2,314.47% |
| Diluted EPS (TTM) | -1.84 |
| Quarterly Revenue Growth (YOY) | 112.60% |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 19.98 |
| Operating Cash Flow (TTM) | -140.43 M |
| Levered Free Cash Flow (TTM) | -99.00 M |
| Return on Assets (TTM) | -18.15% |
| Return on Equity (TTM) | -31.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | NewAmsterdam Pharma Company N.V | Bearish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.38 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.39% |
| % Held by Institutions | 111.32% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (Stifel, 41.00%) | Buy |
| Median | 47.50 (33.95%) | |
| Low | 45.00 (Guggenheim, 26.90%) | Buy |
| Average | 47.50 (33.95%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 34.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 19 Feb 2026 | 45.00 (26.90%) | Buy | 34.63 |
| Needham | 18 Feb 2026 | 48.00 (35.36%) | Buy | 35.76 |
| RBC Capital | 21 Jan 2026 | 47.00 (32.54%) | Buy | 33.94 |
| Stifel | 16 Dec 2025 | 50.00 (41.00%) | Buy | 34.22 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Feb 2026 | Announcement | NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit |
| 09 Jan 2026 | Announcement | NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities |
| 05 Jan 2026 | Announcement | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Dec 2025 | Announcement | NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |